|1.||Calvani, Menotti: 11 articles (01/2009 - 12/2002)|
|2.||Nicolai, Raffaella: 8 articles (10/2013 - 12/2002)|
|3.||Malaguarnera, Mariano: 7 articles (05/2014 - 12/2006)|
|4.||Vacante, Marco: 7 articles (05/2014 - 03/2008)|
|5.||Malaguarnera, Michele: 6 articles (05/2014 - 03/2008)|
|6.||Wiberg, Mikael: 6 articles (01/2012 - 07/2002)|
|7.||Rampello, Liborio: 6 articles (12/2011 - 12/2006)|
|8.||Calvani, M: 6 articles (08/2007 - 01/2000)|
|9.||Ghelardini, Carla: 5 articles (06/2014 - 12/2002)|
|10.||Koverech, Aleardo: 5 articles (10/2013 - 09/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
09/01/2002 - "Clinical trials of acetyl-l-carnitine indicate that it is well-tolerated and may be effective in younger Alzheimer's disease patients and may be an effective adjuvant treatment. "
06/01/2004 - "Acetyl-L-carnitine (ALC), a naturally occurring endogenous compound, has been shown to improve the cognitive performance of patients with senile dementia Alzheimer's type, and to be involved in cholinergic neurotransmission. "
09/01/2002 - "Augmentation of brain levels of acetyl-l-carnitine, an endogenous molecule, may help to reverse membrane phospholipid changes in Alzheimer's disease. "
01/01/1994 - "This suggests an explanation of the positive results obtained with ALCAR in the treatment of Alzheimer's disease."
11/01/1991 - "In a double-blind, placebo-controlled, parallel-group, randomized clinical trial, we studied the efficacy of long-term (1-year) oral treatment with acetyl-L-carnitine in 130 patients with a clinical diagnosis of Alzheimer's disease. "
05/01/2007 - "There was no statistically significant difference in changes in VAS over 14 days between groups for the intent-to-treat (ITT) population, but for the efficacy-evaluable (EE) population ALCAR treatment produced a significantly greater reduction in pain compared with placebo (P=0.022). "
01/01/2009 - "This study was designed to determine the short-term effect of acetyl-l-carnitine (ALC) on symptoms of withdrawal in opiate-dependent subjects and animals and, in particular, on pain, given the efficacy of ALC in other typologies of pain. "
02/17/2010 - "Aimed to explore the link between pain and neuroregeneration, the effect of ALCAR treatment (100 mg kg(-1) i.p. "
05/01/2007 - "ALCAR, administered twice a day intramuscularly to HIV-1-infected patients with symptomatic ATN, significantly reduced weekly mean pain ratings on the VAS compared with placebo. "
06/13/2014 - "Prophylactic role of acetyl-l-carnitine on knee lesions and associated pain in a rat model of osteoarthritis."
05/01/2014 - "In subjects treated with Acetyl-L-Carnitine supplementation we observed increased daily activity and reduced presenteeism and fatigue. "
06/01/2013 - "Acetyl-L-carnitine treatment decreases the severity of mental and physical fatigue, depression cognitive impairment and improves health-related quality of life. "
03/01/2008 - "To determine the efficacy, tolerability and impact on the fatigue, as well as on cognitive and functional status of elderly subjects with acetyl L-carnitine (ALC), 96 aged subjects (>70 years, range 71-88) were investigated (50 females and 46 males; mean age 76.2+/-7.6 and 78.4+/-6.4 years, respectively). "
03/01/2008 - "Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue."
06/01/2003 - "The fatigue sensation is somehow related to hypofunction of the glutamatergic system through reduced uptake of acetyl-carnitine in the discrete brain regions. "
01/01/2003 - "The objective of this review is to establish whether Acetyl-l-carnitine is clinically effective in the treatment of people with dementia. "
01/01/1988 - "It is possible to affirm that the acetyl-L-carnitine treated patients showed statistically significant improvement in the behavioural performances (Blessed Dementia Scale p less than 0.02; Stuard Hospital Geriatric Rating Scale p less than 0.01), in the memory tests (Rey short-term p less than 0.02; Rey long-term p less than 0.05; Corsi p less than 0.05), in the attention test (Barrage test p less than 0.01) and in the Verbal Fluency test p less than 0.01)."
01/01/1990 - "Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia."
01/01/1989 - "Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine."
01/01/2003 - "Acetyl-L-carnitine for dementia."
04/01/2012 - "Becasue mitochondrial biogenesis could be a possible mechanism for ALCAR-induced improvement in bioenergetics in neurons, the present study aimed at exploring signaling pathways of ALCAR-induced neuroprotection in hypoxia and possible occurrence of mitochondrial biogenesis. "
06/30/2009 - "The results displayed reference memory impairment in Sprague-Dawley rats exposed to hypobaric hypoxia (7620 m) for 14 consecutive days which however improved on administration of ALCAR during hypoxic exposure. "
06/30/2009 - "The present study therefore reveals the therapeutic potential of ALCAR under conditions of hypobaric hypoxia and elucidates a novel mechanism of action of the drug."
04/01/2012 - "Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis."
09/10/2007 - "These results suggested that supplementation with acetyl-L-carnitine improves spatial working memory deficits reduces oxidative stress and inhibits apoptotic cascade induced by hypoxia."
|3.||Folic Acid (Vitamin M)
|1.||Self Administration (Administration, Self)
|2.||Prostatectomy (Retropubic Prostatectomy)
|3.||Drug Therapy (Chemotherapy)